Alefacept for Alopecia Areata

Heffernan, Michael; Hurley, M. Yadira; Martin, Kathleen; Smith, Jeremy C.; Anadkat, Milan J.

doi:10.1001/archderm.141.12.1513

Cited by 28 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recent report, methotrexate alone or in combination with low doses of corticosteroids was effective in severe long-term AA [35]. Alefacept, which is a lymphocyte-function-associated antigen 3/IgG fusion protein that blocks T cell activation, has also been used for recalcitrant AA and has achieved some degree of improvement [36]. …”

Section: Discussionmentioning

confidence: 99%

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

Nakajima

Inui

Itami³

2007

Dermatology

View full text Add to dashboard Cite

Background/Aim: Recent reports of pulse corticosteroid therapy for alopecia areata (AA) show its efficacy for patients with a history of ≤1 year but not for recalcitrant cases or alopecia totalis/universalis. The purpose of this study was to evaluate the efficacy and safety of pulse corticosteroid therapy for recent-onset AA patients. Method: A total of 139 severe AA patients aged >15 years were included in this study. The duration from the onset of active hair loss was within 12 months for 125 (89.9%) of those patients. Results: Of the patients, 72.7% had hair loss on >50% of their scalp area. Among the recent-onset group (duration of AA ≤6 months), 59.4% were good responders (>75% regrowth of alopecia lesions), while 15.8% with >6 months duration showed a good response. Recent-onset AA patients with less severe disease (≤50% hair loss) responded at a rate of 88.0%, but only 21.4% of recent-onset patients with 100% hair loss responded. No serious adverse effects were observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

Nakajima

Inui

Itami³

2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…This is consistent with recent findings for other single-targeted psoriasis treatments that did not demonstrate efficacy in the treatment of AA. 21,22 Indeed, it has been reported that patients who were being treated with antietumor necrosis factor agents have developed AA during the course of treatment. 23,24 Given the involvement of T cells in the pathophysiology of AA, and that most of the treatments that have been effective in psoriasis have also been effective in the treatment of AA, it may be worth examining in more detail why efalizumab was not efficacious in the treatment of AA in this study.…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous efalizumab is not effective in the treatment of alopecia areata

Price¹,

Hordinsky²,

Olsen³

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…[309][310][311][312] One case series has been reported on the use of alefacept in 4 patients with alopecia areata/alopecia universalis. 313 Patients were treated with alefacept, 15 mg weekly, for 12 weeks. Some patients remained on a stable regimen of intralesional steroids throughout the treatment course.…”

Section: Off-label Uses Of Alefaceptmentioning

confidence: 99%